Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

Bortezomib (Velcade) is used widely for the treatment of various human cancers; however, its mechanisms of action are not fully understood, particularly in myeloid malignancies. Bortezomib is a selective and reversible inhibitor of the proteasome. Paradoxically, we find that bortezomib induces prote...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Fang, Jing, Rhyasen, Garrett, Bolanos, Lyndsey, Rasch, Christopher, Varney, Melinda, Wunderlich, Mark, Goyama, Susumu, Jansen, Gerrit, Cloos, Jacqueline, Rigolino, Carmela, Cortelezzi, Agostino, Mulloy, James C., Oliva, Esther N., Cuzzola, Maria, Starczynowski, Daniel T.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2012
Θέματα:
Myeloid Neoplasia
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3412348/
https://ncbi.nlm.nih.gov/pubmed/22685174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-407999
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια